Asset profile
itepekimab
Monoclonal antibody
Evidence outlook · lead readout
AERIFY-1 (NCT04701983) · Chronic Obstructive Pulmonary Disease
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
AERIFY-1 (NCT04701983): This randomized, quadruple-blind, placebo-controlled trial enrolled 1,127 patients and measured the annualized rate of moderate or severe COPD flare-ups, a standard clinical outcome for COPD, over 52 weeks. Itepekimab significantly reduced this rate by 27% versus placebo in the every-2-week dosing group.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
43 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 41 same-indication; 15 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Itepekimab: this drug | Phase 3 | Monoclonal antibody | IL-33 | ||
| Tozorakimab | Phase 3 | Monoclonal antibody | IL-33 | ||
| GSK3862995 | Phase 1 | Monoclonal antibody | IL-33 | ||
| Aclidinium Bromide (Tudorza Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Benralizumab (Fasenra) | Approved | Monoclonal antibody | IL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophils | ||
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | ||
| Depemokimab | Approved | Monoclonal antibody | IL-5 | ||
| Ensifentrine (Ohtuvayre) | Approved | Small molecule | PDE3/PDE4 | ||
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | ||
| Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Mepolizumab (Nucala) | Approved | Monoclonal antibody | IL-5, Interleukin-5 (IL-5), ligand-neutralizing | ||
| Olodaterol | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Olodaterol / Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Revefenacin (Yupelri) | Approved | Small molecule | Muscarinic receptors (antagonist) | ||
| Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) |
…and 28 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
October 2026 (1)
What to watch
November 2026 (1)
What to watch
2027 (1)
February 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.